CORONA Remedies: Reg 74(5) Certificate for Q4 FY26 Not Applicable
CORONA Remedies Limited received a certificate for Q4 FY26 stating Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, is not applicable. This is due to the company's shares being entirely in demat form with no rematerialization or dematerialization requests received during the quarter ended March 31, 2026.
This is a standard regulatory filing confirming the non-applicability of a specific regulation due to the company's shares being in demat form. It does not introduce new material information that would affect the company's operations or market valuation.
The announcement is a routine compliance filing and does not contain any new financial information or strategic developments that would impact the company's stock positively or negatively.
CORONA Remedies Limited has submitted a certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the fourth quarter ended March 31, 2026. The company's Registrar and Share Transfer Agent, Bigshare Services Private Limited, confirmed that the said regulation is not applicable to CORONA Remedies Limited.
This is because the entire holding of the company's shares are in demat form, and no requests for rematerialization or dematerialization were received from any members during the quarter ended March 31, 2026. The period for the confirmation was from December 31, 2025, to March 31, 2026.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.